Claims for Patent: 7,641,900

Summary for Patent: 7,641,900

Title:	Wound treatment utilizing collagenase and a phosphotidylcholine organogel
Abstract:	The effect of the action of collagenase in treating lesions containing collagen or mixed fibrin clots (e.g., burns or ulcers) is improved by applying collagenase to the wound in combination with an organogel and a phosphatidylcholine, of which lecithin is a readily available source, particularly when the collagenase is first mixed and stored with that choline and an organic solvent and is subsequently mixed with a second individually stored formulation comprising a gel-forming agent and water, the two formulations individually having satisfactory shelf lives and the resultant mixture being applied to the lesion promptly after being formed.
Inventor(s):	Soroff; Harry (Northport, NY), Simon; Marcia (Stony Brook, NY), Fallon; Thomas (Saratoga Springs, NY), Fallon; Peter (Loudonville, NY), Hatch; Gabriele (Setauket, NY)
Assignee:	Research Foundation of State University of New York (Albany, NY)
Application Number:	11/093,540
Patent Claims:	1. A method for debridement of lesions containing collagen or mixed fibrin clots resulting from burns or ulcers which comprises applying to said lesion a mixture of collagenase and a phosphatidylcholine organogel. 2. A method for debridement of lesions containing collagen or mixed fibrin clots resulting from burns or ulcers which comprises applying to said lesion a mixture of collagenase and a lecithin organogel. 3. The method of claim 1, in which said phosphatidylcholine organogel comprises phosphatidylcholine, an organic solvent, water and a gel forming agent. 4. The method of claim 2, in which said lecithin organogel comprises lecithin, an organic solvent, water and a gel-forming agent. 5. The method of either of claims 3 or 4, in which said organic solvent is a member of the group consisting of organic transdermal absorption enhancers. 6. The method of either of claims 3 or 4, in which said organic solvent is a member of the group consisting of organic transdermal absorption enhancers and said gel-forming agent is a member of the group consisting of poloxamer compounds and polymers of crosslinked acrylic acid. 7. The method of claim 6, in which said organic solvent is a member of the group consisting of ethanol, isopropyl palmitate, isopropyl myristate and ethoxy diglycol. 8. The method of claim 1, in which said mixture is formed by first separately producing first and second formulations and then mixing those formulations together and applying the resultant mixture to the lesion, said first formulation being a non-aqueous phase comprising phosphatidylcholine, an organic solvent and collagenase and said second formulation being an aqueous phase comprising a gel-forming agent and water. 9. The method of claim 2, in which said mixture is formed by first separately producing first and second formulations and then mixing those formulations together and applying the resultant mixture to the lesion, said first formulation being a non-aqueous phase comprising lecithin, an organic solvent and collagenase and said second formulation being an aqueous phase comprising a gel forming agent and water. 10. The method of claim 1, in which said mixture is formed by first separately producing first and second formulations and then mixing those formulations together and applying the resultant mixture to the lesion, said first formulation being a non-aqueous phase comprising phosphatidylcholine and said organic solvent in approximately equal portions by weight and with said collagenase present in quantities of about 125 or higher units per milliliter of the final combination, said second formulation being an aqueous phase comprising said gel-forming agent and said water in approximately the proportions of 10 gms of gel-forming agent to 50 ml of water. 11. The method of claim 2, in which said mixture is formed by first separately producing first and second formulations and then mixing those formulations together and applying the resultant mixture to the lesion, said first formulation being a non-aqueous phase comprising lecithin and said organic solvent in approximately equal proportions by weight and with said collagenase present in quantities of about 125 or higher units per milliliter of the final combination, said second formulation being an aqueous phase comprising said gel-forming agent and said water in approximately the proportions of 10 gins of gel-forming agent to 50 ml of water. 12. The method of claim 10, in which said first formulation also comprises ascorbic acid and said second formulation also comprises potassium sorbate. 13. The method of claim 11, in which said first formulation also comprises ascorbic acid and said second formulation also comprises potassium sorbate. 14. The method of claim 10, in which said first formulation also comprises a small amount of potassium sorbate.

Details for Patent 7,641,900

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29